|Source of information||What is the information?||How can it be used?|
|Update of prior systematic review||
Nonfatal Intracranial Bleed (severe): 0.1 to 0.51
Nonfatal Intracranial Bleed (moderate): 0.29 to 0.77
Nonfatal Intracranial Bleed (mild): 0.47 to 0.94
Nonfatal Pulmonary Embolism: 0.63
Major Bleed: 0.44 to 0.84
“This result suggested intracranial bleed overall was 2 to 3 times worse than major bleed or pulmonary embolism.”
|To help guideline panellists weigh the benefits (absolute reduction in pulmonary embolism) and harms (absolute increase in bleedings).|
For the guideline on management of breast lump and primary breast cancer, the systematic review identified one study reporting an additional year in life expectancy or 3% in survival rates were sufficient to make adjuvant chemotherapy worthwhile by 68–84% of women.
|To judge to what extent women are willing to accept the burden of adjuvant chemotherapy to benefit from a specific amount of increased survival|
“Evidence from qualitative studies suggested women may fear screening and may have a high level of anxiety related to colposcopy or treatment.”
|To suggest what are the views of local women on cervical cancer screening tests in relation to its psychological impact|
|Panel members (either physicians or patients)||
In some guideline topics, patient inputs corroborated the panel’s perception.
|To serve as complementary sources in addition to the information from systematic review.|